BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be sufficient because of tumor heterogeneity. A focus on examining global biomarker expression or activity, particularly in microscopic residual chemotherapy-resistant disease, is needed for the appropriate selection of targeted therapies. This study was aimed at establishing a technique for the assessment of biomarkers of ovarian cancer peritoneal spread. METHODS: An in-house developed fluorescent imaging device was used to detect the expression of the c-Met oncogene in ovarian cancer. A modified cyanine 5-tagged peptide, GE137, with a high in vitro affinity for the human c-Met protein, was tested in a panel of ovarian cancer cell lines. Finally, the...
Detecting early cancer through liquid biopsy is challenging due to the lack of specific biomarkers f...
OBJECTIVES:c-Met is a receptor tyrosine kinase shown inappropriate expression and actively involved ...
AbstractPatients with metastatic ovarian cancer continue to have a dismal prognosis, emphasizing the...
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be suffi...
Background The c-Met protein is overexpressed in many gastrointestinal cancers. We explored EMI-1...
<div><p>Epithelial ovarian cancer (EOC) is the seventh most common cancer among women worldwide. The...
Objective: c-Met is expressed in human ovarian cancer tissues, and its phosphorylation activates sig...
In epithelial ovarian cancer (EOC), the strongest prognostic factor is the completeness of surgery. ...
Background: The incidence of oesophageal cancer is rising worldwide, yet the surveillance of patient...
Most patients with epithelial ovarian cancer (EOC) experience drug-resistant disease recurrence. Ide...
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of resea...
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of resea...
Objective: Tyrosine-protein kinase MET (c-MET) has been reported to be a prognostic marker and suita...
Epithelial ovarian cancer is the most lethal gynecologic malignancy in the United States. Although p...
Chemokine CXCL12 and receptor CXCR4 have emerged as promising therapeutic targets for ovarian cancer...
Detecting early cancer through liquid biopsy is challenging due to the lack of specific biomarkers f...
OBJECTIVES:c-Met is a receptor tyrosine kinase shown inappropriate expression and actively involved ...
AbstractPatients with metastatic ovarian cancer continue to have a dismal prognosis, emphasizing the...
BACKGROUND: Standard biomarker testing of a single macroscopic disease site is unlikely to be suffi...
Background The c-Met protein is overexpressed in many gastrointestinal cancers. We explored EMI-1...
<div><p>Epithelial ovarian cancer (EOC) is the seventh most common cancer among women worldwide. The...
Objective: c-Met is expressed in human ovarian cancer tissues, and its phosphorylation activates sig...
In epithelial ovarian cancer (EOC), the strongest prognostic factor is the completeness of surgery. ...
Background: The incidence of oesophageal cancer is rising worldwide, yet the surveillance of patient...
Most patients with epithelial ovarian cancer (EOC) experience drug-resistant disease recurrence. Ide...
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of resea...
Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of resea...
Objective: Tyrosine-protein kinase MET (c-MET) has been reported to be a prognostic marker and suita...
Epithelial ovarian cancer is the most lethal gynecologic malignancy in the United States. Although p...
Chemokine CXCL12 and receptor CXCR4 have emerged as promising therapeutic targets for ovarian cancer...
Detecting early cancer through liquid biopsy is challenging due to the lack of specific biomarkers f...
OBJECTIVES:c-Met is a receptor tyrosine kinase shown inappropriate expression and actively involved ...
AbstractPatients with metastatic ovarian cancer continue to have a dismal prognosis, emphasizing the...